(Q36978911)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955213%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

meta-analysis

0 references

title

Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955213%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955213%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

S Weinmann

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955213%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

T Becker

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955213%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

23 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955213%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955213%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

196

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955213%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955213%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

511-20; discussion 521-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17955213%20AND%20SRC:MED&resulttype=core&format=json

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

9 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-007-0975-9

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-007-0975-9

Systematic Reviews in Health Care

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-007-0975-9

Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo

21 January 2018

1 reference

12 December 2020

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia

1 reference

12 December 2020

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

12 December 2020

Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia

1 reference

12 December 2020

Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

1 reference

12 December 2020

Imputing variance estimates do not alter the conclusions of a meta-analysis with continuous outcomes: a case study of changes in renal function after living kidney donation

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

12 December 2020

Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms

1 reference

12 December 2020

Venlafaxine for major depression

1 reference

12 December 2020

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

12 December 2020

Venlafaxine Versus Fluvoxamine in the Treatment of Delusional Depression

1 reference

12 December 2020

Multiple recurrences of major depressive disorder.

1 reference

12 December 2020

A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients

1 reference

12 December 2020

A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.

1 reference

12 December 2020

Achieving gains beyond response.

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

12 December 2020

"Wish bias" in antidepressant drug trials?

1 reference

12 December 2020

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

1 reference

12 December 2020

Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials

1 reference

12 December 2020

Measuring inconsistency in meta-analyses

1 reference

12 December 2020

Prevalence and treatment of mental disorders, 1990 to 2003

1 reference

12 December 2020

Meta-analytical studies on new antidepressants.

1 reference

12 December 2020

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis

1 reference

12 December 2020

Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis

1 reference

12 December 2020

The efficacy of antidepressants in the treatment of late-life depression

1 reference

12 December 2020

Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy.

1 reference

12 December 2020

A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression

1 reference

12 December 2020

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

12 December 2020

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram

1 reference

12 December 2020

Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

12 December 2020

Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.

1 reference

12 December 2020

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

12 December 2020

Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group

1 reference

12 December 2020

Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database

1 reference

12 December 2020

Assessment of methodological quality of primary studies by systematic reviews: results of the metaquality cross sectional study

1 reference

12 December 2020

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

12 December 2020

Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors

1 reference

12 December 2020

Is the cutoff to define remission on the Hamilton Rating Scale for Depression too high?

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Imputing missing standard deviations in meta-analyses can provide accurate results

1 reference

12 December 2020

Venlafaxine and SSRI remission data revisited

1 reference

12 December 2020

A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression

1 reference

12 December 2020

Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond

1 reference

12 December 2020

Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review

1 reference

12 December 2020

Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression

1 reference

12 December 2020